MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, is investing $76 million to expand its ADC manufacturing capabilities and capacity at its Bioconjugation Center of Excellence facility in St. Louis, Missouri.
 
This investment will triple existing capacity and enhance the company’s contract development and manufacturing organization (CDMO) offering, reinforcing its commitment to clients and patients.
 
With additional capacity and by scaling utilities and enhancing Process and Analytical Development (PAD) labs, MilliporeSigma aims to provide industry-leading support for early-stage and commercial bioconjugates. The company’s goal is to ensure clients can bring their innovations to market more effectively and with shorter turnaround times.
 
“We are shaping tomorrow’s cancer care, today. With this investment, we are not just enhancing our capabilities; we are investing in our clients’ success by accelerating innovation and development to ultimately deliver novel therapies to patients more quickly,” said Benjamin Hein, Head of Life Science Services, Life Science business of Merck KGaA, Darmstadt, Germany. “ADCs represent a transformative approach to oncology, enabling targeted therapies that minimize damage to healthy tissues. As the market for this novel modality grows and the medical community adopts them as first-line treatments, it may mean that fewer patients need invasive treatments like chemotherapy and radiation that cause significant side effects.”
 
The ADC capacity expansion project will:
 

• Upgrade 34,000 square feet to benefit the Process and Analytical Development, Quality Control, Research and Development, Manufacturing, and Logistics departments.
• Add new labs, a dedicated manufacturing buffer preparation facility, and a cold storage and a GMP-controlled room temperature (CRT) warehouse that will be located close to the existing facility.

• More than €300 million ($325 million) into a new Bioprocessing Production Center in Daejeon, South Korea.
• A new €290 million biosafety testing facility in Rockville, MD.